|
Market Closed -
Euronext Paris
19:55:00 03/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 2.380 EUR | +1.71% |
|
+0.85% | -20.67% |
| 08-10 | ABL Diagnostics Plans Listing Transfer to Euronext Growth Paris | MT |
| 07-23 | French Court OKs ABL Diagnostics' Industrial Plan to Acquire Texcell | MT |
Company Valuation: ABL Diagnostics
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 2.96 | 3.988 | 29 | 156.3 | 39.64 | 48.34 |
| Change | - | 34.75% | 627.14% | 439.03% | -74.64% | 21.95% |
| Enterprise Value (EV) 1 | 0.6006 | 1.286 | 30.64 | 157.5 | 41.66 | 49.27 |
| Change | - | 114.05% | 2,283.25% | 414.19% | -73.55% | 18.27% |
| P/E | -33.1x | 15.5x | 206x | 2,876x | 123x | 50x |
| PBR | 1.25x | 1.52x | 34.5x | 23.1x | 5.29x | 6.32x |
| PEG | - | -0x | -4.5x | -30.2x | 0x | 0x |
| Capitalization / Revenue | - | 221,548,833,333x | 3,097,618x | 25,256,446x | 6,753,666x | 6,068,760x |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| EV / EBIT | -6.59x | -12.5x | 517x | -240x | -85x | 155x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | 0.05 | 0.11 |
| Rate of return | - | - | - | - | 2.03% | 3.67% |
| EPS 2 | -0.0445 | 0.1285 | 0.07 | 0.003373 | 0.02 | 0.06 |
| Distribution rate | - | - | - | - | 250% | 183% |
| Net sales | - | 0.000018 | 9.361 | 6.189 | 5.869 | 7.966 |
| EBITDA | - | - | 0.62 | 0.005134 | 0.2459 | 0.4283 |
| EBIT 1 | -0.0912 | -0.1026 | 0.0593 | -0.6571 | -0.4904 | 0.3171 |
| Net income 1 | -0.0893 | 0.2579 | 1.106 | 0.0544 | 0.2852 | 0.9867 |
| Net Debt 1 | -2.359 | -2.702 | 1.643 | 1.244 | 2.024 | 0.9326 |
| Reference price 2 | 1.475 | 1.988 | 14.452 | 9.700 | 2.460 | 3.000 |
| Nbr of stocks (in thousands) | 2,006 | 2,006 | 2,006 | 16,114 | 16,114 | 16,114 |
| Announcement Date | 23/04/21 | 20/05/22 | 01/08/23 | 31/07/24 | 06/05/25 | 07/05/26 |
1EUR in Million2EUR
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 43.59M | |
| 31.69x | 4.28x | 16.43x | 2.33% | 191B | |
| 19.8x | 3.57x | 12.75x | 3.17% | 118B | |
| 18.42x | 0.21x | 13.39x | 0.71% | 64.19B | |
| 29.93x | 7.38x | 19.05x | 1.33% | 51.49B | |
| 36.14x | 3.47x | 11.9x | 2.09% | 51.08B | |
| 35.95x | 6.33x | 19.86x | -.--% | 33.85B | |
| 46.86x | 1.34x | 12.44x | 0.2% | 31.85B | |
| 39.96x | 7x | 25.11x | 0.26% | 24.11B | |
| 18.71x | 2.93x | 10.5x | 1.5% | 22.96B | |
| Average | 30.83x | 4.06x | 15.71x | 1.29% | 58.87B | |
| Weighted average by Cap. | 28.99x | 3.91x | 15.30x | 1.85% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ABLD Stock
- Valuation ABL Diagnostics
Select your edition
All financial news and data tailored to specific country editions
